Impact of the Coronavirus Disease 2019 Pandemic on Hospital Admissions for Idiopathic Pulmonary Fibrosis: a Nationwide Population-based Study

Overview

Journal BMC Pulm Med

Publisher Biomed Central

Specialty Pulmonary Medicine

Date 2024 Aug 31

PMID 39217306

Authors

In-So Cho

Jihye Lim

Min-Seok Chang

Ji-Ho Lee

Affiliations

Soon will be listed here.

Abstract

Background: Previous studies have consistently reported a decrease in hospital admissions for respiratory diseases during the coronavirus disease 2019 (COVID-19) pandemic. However, the impact of the pandemic on idiopathic pulmonary fibrosis (IPF) admissions remains unknown.

Methods: This study used data from the Korean National Health Insurance Service database. IPF was defined based on the International Classification of Diseases 10th Revision (ICD-10) and rare intractable disease (RID) codes. The rate of IPF admissions was calculated by dividing the number of IPF admissions by the prevalence of IPF. The rate of IPF admissions during the COVID-19 pandemic (2020-2021) was compared with the mean rate of admissions during the prepandemic period (2017-2019) and presented as the rate ratio (RR). A sensitivity analysis was conducted on patients treated with systemic corticosteroids during IPF admission.

Results: In patients with IPF defined based on the ICD-10 (analysis 1), the RRs significantly decreased from March in 2020 to December 2021, except for June and September in 2020. Similarly, in patients with IPF defined based on the ICD-10 and RID (analysis 2), the RRs significantly decreased from March 2020 to December 2021, except for June and September 2020. In the sensitivity analysis of analysis 1, the RR significantly decreased in 2020 (0.93; 95%CI: 0.88-0.99; P = 0.029), whereas the RR in 2021 was not significantly different. The RRs in the sensitivity analysis of analysis 2 significantly decreased to 0.85 (0.79-0.92; P < 0.001) in 2020 and 0.82 (0.76-0.88; P < 0.001) in 2021. In the subgroup analysis, the rates of IPF admissions significantly decreased in 2020 and 2021 across both sexes, patients aged ≥ 60 years, and all household income groups.

Conclusions: The rate of IPF admissions significantly decreased during the COVID-19 pandemic. This result indicates that preventive measures against COVID-19 may effectively mitigate IPF exacerbation. Therefore, it is assumed that there is a close relationship between respiratory viral infections and IPF exacerbations.

References

Seong S, Kim Y, Khang Y, Park J, Kang H, Lee H . Data Resource Profile: The National Health Information Database of the National Health Insurance Service in South Korea. Int J Epidemiol. 2016; 46(3):799-800. PMC: 5837262. DOI: 10.1093/ije/dyw253. View

Pergolizzi Jr J, LeQuang J, Varrassi M, Breve F, Magnusson P, Varrassi G . What Do We Need to Know About Rising Rates of Idiopathic Pulmonary Fibrosis? A Narrative Review and Update. Adv Ther. 2023; 40(4):1334-1346. PMC: 9872080. DOI: 10.1007/s12325-022-02395-9. View

Ravindra K, Singh T, Vardhan S, Shrivastava A, Singh S, Kumar P . COVID-19 pandemic: What can we learn for better air quality and human health?. J Infect Public Health. 2022; 15(2):187-198. PMC: 8642828. DOI: 10.1016/j.jiph.2021.12.001. View

George P, Wells A, Gisli Jenkins R . Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020; 8(8):807-815. PMC: 7228727. DOI: 10.1016/S2213-2600(20)30225-3. View

Collard H, Ryerson C, Corte T, Jenkins G, Kondoh Y, Lederer D . Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 2016; 194(3):265-75. DOI: 10.1164/rccm.201604-0801CI. View

Maher T, Bendstrup E, Dron L, Langley J, Smith G, Khalid J . Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res. 2021; 22(1):197. PMC: 8261998. DOI: 10.1186/s12931-021-01791-z. View

Shen H, Zhang N, Liu Y, Yang X, He Y, Li Q . The Interaction Between Pulmonary Fibrosis and COVID-19 and the Application of Related Anti-Fibrotic Drugs. Front Pharmacol. 2022; 12:805535. PMC: 8766975. DOI: 10.3389/fphar.2021.805535. View

Lee J, Park H, Kim S, Kim Y, Kim H . Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study. BMC Pulm Med. 2023; 23(1):54. PMC: 9898951. DOI: 10.1186/s12890-023-02340-8. View

Goto Y, Sakamoto K, Fukihara J, Suzuki A, Omote N, Ando A . COVID-19-Triggered Acute Exacerbation of IPF, an Underdiagnosed Clinical Entity With Two-Peaked Respiratory Failure: A Case Report and Literature Review. Front Med (Lausanne). 2022; 9:815924. PMC: 8850347. DOI: 10.3389/fmed.2022.815924. View

10.

Ojha V, Mani A, Pandey N, Sharma S, Kumar S . CT in coronavirus disease 2019 (COVID-19): a systematic review of chest CT findings in 4410 adult patients. Eur Radiol. 2020; 30(11):6129-6138. PMC: 7261039. DOI: 10.1007/s00330-020-06975-7. View

11.

Wootton S, Kim D, Kondoh Y, Chen E, Lee J, Song J . Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 183(12):1698-702. PMC: 3136996. DOI: 10.1164/rccm.201010-1752OC. View

12.

Yoon H, Kim H, Kim Y, Song J . Prevalence and incidence of sarcoidosis in Korea: a nationwide population-based study. Respir Res. 2018; 19(1):158. PMC: 6114796. DOI: 10.1186/s12931-018-0871-3. View

13.

Chen C, So M, Liu F . Assessing government policies' impact on the COVID-19 pandemic and elderly deaths in East Asia. Epidemiol Infect. 2022; 150:e161. PMC: 9472036. DOI: 10.1017/S0950268822001388. View

14.

Shah S, Quint J, Nwaru B, Sheikh A . Impact of COVID-19 national lockdown on asthma exacerbations: interrupted time-series analysis of English primary care data. Thorax. 2021; 76(9):860-866. PMC: 8011425. DOI: 10.1136/thoraxjnl-2020-216512. View

15.

Olsen S, Azziz-Baumgartner E, Budd A, Brammer L, Sullivan S, Pineda R . Decreased influenza activity during the COVID-19 pandemic-United States, Australia, Chile, and South Africa, 2020. Am J Transplant. 2020; 20(12):3681-3685. PMC: 7753605. DOI: 10.1111/ajt.16381. View

16.

Saqib M, Siddiqui S, Qasim M, Jamil M, Rafique I, Awan U . Effect of COVID-19 lockdown on patients with chronic diseases. Diabetes Metab Syndr. 2020; 14(6):1621-1623. PMC: 7450263. DOI: 10.1016/j.dsx.2020.08.028. View

17.

Halpin D, Vogelmeier C, Agusti A . COVID-19 and COPD: lessons beyond the pandemic. Am J Physiol Lung Cell Mol Physiol. 2021; 321(5):L978-L982. PMC: 8598249. DOI: 10.1152/ajplung.00386.2021. View

18.

Huh K, Kim Y, Ji W, Kim D, Lee E, Kim J . Decrease in hospital admissions for respiratory diseases during the COVID-19 pandemic: a nationwide claims study. Thorax. 2021; 76(9):939-941. DOI: 10.1136/thoraxjnl-2020-216526. View

19.

Kim M, Kweon O, Lim Y, Choi S, Chung J, Lee M . Impact of social distancing on the spread of common respiratory viruses during the coronavirus disease outbreak. PLoS One. 2021; 16(6):e0252963. PMC: 8202938. DOI: 10.1371/journal.pone.0252963. View

20.

Ahn I, Park D, Hann H, Kim K, Kim H, Ahn H . Incidence, prevalence, and survival of moyamoya disease in Korea: a nationwide, population-based study. Stroke. 2014; 45(4):1090-5. DOI: 10.1161/STROKEAHA.113.004273. View